Effective Pharmacologic Management of Alzheimer's Disease

Martin Farlow, Jeffrey L. Cummings

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

In order to assist physicians in the effective pharmacologic management of this challenging population, evidence-based pharmacologic treatment algorithms for the different stages of Alzheimer's disease have been developed. Evidence-based guidelines outlining pharmacotherapeutic strategies can be systematically implemented to optimize outcomes for patients in different stages of Alzheimer's disease. The first step toward the best possible long-term management is early diagnosis of Alzheimer's disease, thereby facilitating early initiation of cholinesterase inhibitor treatment, which may stabilize/reduce the rate of symptomatic cognitive and functional decline. Cholinesterase inhibitor therapy with rivastigmine, donepezil, or galantamine is endorsed as standard first-line therapy in patients with mild-to-moderate Alzheimer's disease. The N-methyl-D-aspartate receptor-antagonist, memantine, may be used as monotherapy or in combination with a cholinesterase inhibitor for patients with moderate Alzheimer's disease, and as monotherapy for patients with severe Alzheimer's disease. During treatment, cognitive and functional status should be monitored over 6-month intervals, and pharmacologic therapy should ideally be continued until there are no meaningful social interactions and quality of life has irreversibly deteriorated.

Original languageEnglish
Pages (from-to)388-397
Number of pages10
JournalThe American Journal of Medicine
Volume120
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Alzheimer Disease
Cholinesterase Inhibitors
Rivastigmine
Therapeutics
Galantamine
Memantine
Interpersonal Relations
N-Methyl-D-Aspartate Receptors
Early Diagnosis
Quality of Life
Guidelines
Physicians
Population

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitor
  • Donepezil
  • Galantamine
  • Management
  • Memantine
  • Pharmacotherapy
  • Rivastigmine

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Effective Pharmacologic Management of Alzheimer's Disease. / Farlow, Martin; Cummings, Jeffrey L.

In: The American Journal of Medicine, Vol. 120, No. 5, 05.2007, p. 388-397.

Research output: Contribution to journalArticle

Farlow, Martin ; Cummings, Jeffrey L. / Effective Pharmacologic Management of Alzheimer's Disease. In: The American Journal of Medicine. 2007 ; Vol. 120, No. 5. pp. 388-397.
@article{f4d515bb3dd2430a9001299ae6765f91,
title = "Effective Pharmacologic Management of Alzheimer's Disease",
abstract = "In order to assist physicians in the effective pharmacologic management of this challenging population, evidence-based pharmacologic treatment algorithms for the different stages of Alzheimer's disease have been developed. Evidence-based guidelines outlining pharmacotherapeutic strategies can be systematically implemented to optimize outcomes for patients in different stages of Alzheimer's disease. The first step toward the best possible long-term management is early diagnosis of Alzheimer's disease, thereby facilitating early initiation of cholinesterase inhibitor treatment, which may stabilize/reduce the rate of symptomatic cognitive and functional decline. Cholinesterase inhibitor therapy with rivastigmine, donepezil, or galantamine is endorsed as standard first-line therapy in patients with mild-to-moderate Alzheimer's disease. The N-methyl-D-aspartate receptor-antagonist, memantine, may be used as monotherapy or in combination with a cholinesterase inhibitor for patients with moderate Alzheimer's disease, and as monotherapy for patients with severe Alzheimer's disease. During treatment, cognitive and functional status should be monitored over 6-month intervals, and pharmacologic therapy should ideally be continued until there are no meaningful social interactions and quality of life has irreversibly deteriorated.",
keywords = "Alzheimer's disease, Cholinesterase inhibitor, Donepezil, Galantamine, Management, Memantine, Pharmacotherapy, Rivastigmine",
author = "Martin Farlow and Cummings, {Jeffrey L.}",
year = "2007",
month = "5",
doi = "10.1016/j.amjmed.2006.08.036",
language = "English",
volume = "120",
pages = "388--397",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effective Pharmacologic Management of Alzheimer's Disease

AU - Farlow, Martin

AU - Cummings, Jeffrey L.

PY - 2007/5

Y1 - 2007/5

N2 - In order to assist physicians in the effective pharmacologic management of this challenging population, evidence-based pharmacologic treatment algorithms for the different stages of Alzheimer's disease have been developed. Evidence-based guidelines outlining pharmacotherapeutic strategies can be systematically implemented to optimize outcomes for patients in different stages of Alzheimer's disease. The first step toward the best possible long-term management is early diagnosis of Alzheimer's disease, thereby facilitating early initiation of cholinesterase inhibitor treatment, which may stabilize/reduce the rate of symptomatic cognitive and functional decline. Cholinesterase inhibitor therapy with rivastigmine, donepezil, or galantamine is endorsed as standard first-line therapy in patients with mild-to-moderate Alzheimer's disease. The N-methyl-D-aspartate receptor-antagonist, memantine, may be used as monotherapy or in combination with a cholinesterase inhibitor for patients with moderate Alzheimer's disease, and as monotherapy for patients with severe Alzheimer's disease. During treatment, cognitive and functional status should be monitored over 6-month intervals, and pharmacologic therapy should ideally be continued until there are no meaningful social interactions and quality of life has irreversibly deteriorated.

AB - In order to assist physicians in the effective pharmacologic management of this challenging population, evidence-based pharmacologic treatment algorithms for the different stages of Alzheimer's disease have been developed. Evidence-based guidelines outlining pharmacotherapeutic strategies can be systematically implemented to optimize outcomes for patients in different stages of Alzheimer's disease. The first step toward the best possible long-term management is early diagnosis of Alzheimer's disease, thereby facilitating early initiation of cholinesterase inhibitor treatment, which may stabilize/reduce the rate of symptomatic cognitive and functional decline. Cholinesterase inhibitor therapy with rivastigmine, donepezil, or galantamine is endorsed as standard first-line therapy in patients with mild-to-moderate Alzheimer's disease. The N-methyl-D-aspartate receptor-antagonist, memantine, may be used as monotherapy or in combination with a cholinesterase inhibitor for patients with moderate Alzheimer's disease, and as monotherapy for patients with severe Alzheimer's disease. During treatment, cognitive and functional status should be monitored over 6-month intervals, and pharmacologic therapy should ideally be continued until there are no meaningful social interactions and quality of life has irreversibly deteriorated.

KW - Alzheimer's disease

KW - Cholinesterase inhibitor

KW - Donepezil

KW - Galantamine

KW - Management

KW - Memantine

KW - Pharmacotherapy

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=34247232644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247232644&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2006.08.036

DO - 10.1016/j.amjmed.2006.08.036

M3 - Article

C2 - 17466645

AN - SCOPUS:34247232644

VL - 120

SP - 388

EP - 397

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5

ER -